Safety of amisulpride (Solian): a review of 11 clinical studies
about
The use of amisulpride in the treatment of acute psychosisThe effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label studyAmisulpride for schizophrenia.The effectiveness and safety of amisulpride in Chinese patients with schizophrenia who switch from risperidone or olanzapine: a subgroup analysis of the ESCAPE study.Effectiveness of amisulpride in Chinese patients with predominantly negative symptoms of schizophrenia: a subanalysis of the ESCAPE study.Efficacy and safety of novel antipsychotics: a critical review.Safety and tolerability of antipsychotics: focus on amisulpride.Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism.Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects.QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial.The potential relationship between QTc interval prolongation and ziprasidone treatment: three cases.Amisulpride-induced dystonia.Amisulpride in the prevention of nausea and vomiting induced by cisplatin-based chemotherapy: a dose-escalation study.A 6-week, randomized, multicentre, open-label study comparing efficacy and tolerability of amisulpride at a starting dose of 400 mg/day versus 800 mg/day in patients with acute exacerbations of schizophrenia.Safety of amisulpride in combination with antidepressants under common clinical practice conditions.Effects of amisulpride on the cognitive function of patients with schizophrenia who switched from risperidone.
P2860
Q24683055-BD0E6313-1392-4AFB-8BD8-852BF92B39B4Q24800019-03CB2262-891E-4E98-B7DB-1D04EACFCE1BQ31083696-BB0DE5ED-B30E-41CB-BF54-1CCBC3F6BC9FQ33609974-99301676-D0DD-49C9-B6C5-72125DC2F657Q33879147-92EB5125-058A-4B3B-B199-D21BB79C0D0FQ34982556-86177CE6-D2B3-45E0-ADFD-F36C6FACD29BQ35026487-84333329-283E-4C64-B70F-736573D7E729Q36725206-CC4D2568-6D73-492F-B011-507629D9F336Q37587289-D78971D7-3158-4F6C-83D6-5DB85DF3A5E7Q38244346-8A019506-29DE-487D-B0F8-85F99F1EE201Q43202107-857FA3CA-DB3F-4D4A-B32E-22CF0AB2552AQ46477497-7F034A07-6E9E-47A4-BA99-6CCCFC53CA46Q46574251-F7777C66-2CD9-4613-AEFB-F376D94721FEQ47744428-3C2D87CC-1793-4BEA-B4EA-A698101D08A8Q48381074-F0B90906-AF9F-432A-A9A4-583822CE0BEAQ48798088-FDFF4667-73C9-4865-8AEF-D78361B73488Q51968316-BCEEA696-2A59-474A-9A7B-E9CCD550F0D7
P2860
Safety of amisulpride (Solian): a review of 11 clinical studies
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Safety of amisulpride (Solian): a review of 11 clinical studies
@ast
Safety of amisulpride (Solian): a review of 11 clinical studies
@en
Safety of amisulpride (Solian): a review of 11 clinical studies
@nl
type
label
Safety of amisulpride (Solian): a review of 11 clinical studies
@ast
Safety of amisulpride (Solian): a review of 11 clinical studies
@en
Safety of amisulpride (Solian): a review of 11 clinical studies
@nl
prefLabel
Safety of amisulpride (Solian): a review of 11 clinical studies
@ast
Safety of amisulpride (Solian): a review of 11 clinical studies
@en
Safety of amisulpride (Solian): a review of 11 clinical studies
@nl
P1476
Safety of amisulpride (Solian): a review of 11 clinical studies
@en
P2093
C Coulouvrat
L Dondey-Nouvel
P304
P356
10.1097/00004850-199907000-00002
P407
P577
1999-07-01T00:00:00Z